Breast Cancer | Specialty

Metastatic HR+ Breast Cancer: Developments and Approvals

July 19th 2018

Dr. Shafaee on the PERSEPHONE Trial in Early-Stage HER2+ Breast Cancer

July 19th 2018

Maryam Nemati Shafaee, MD, assistant professor, Duncan Cancer Center, Lester & Sue Smith Breast Cancer, Baylor College of Medicine, discusses the PERSEPHONE trial in women with early-stage HER2-positive breast cancer.

FDA Grants Sacituzumab Govitecan Priority Review for Triple-Negative Breast Cancer

July 18th 2018

The FDA has granted a priority review designation to a biologics license application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer following at least 2 prior therapies for metastatic disease.

FDA Expands Ribociclib Breast Cancer Approval Under New Pilot Programs

July 18th 2018

The FDA has approved upfront ribociclib for use in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with HR-positive/HER2-negative advanced or metastatic breast cancer. The agency also approved the CDK 4/6 inhibitor for use in combination with fulvestrant for the treatment of postmenopausal women with HR-positive/HER2-negative advanced or metastatic breast cancer, in the frontline setting or after disease progression on endocrine therapy.

Dr. Tolaney on Abemaciclib Plus Pembrolizumab for HR+, HER2- Breast Cancer

July 18th 2018

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the phase Ib results of abemaciclib (Verzenio) plus pembrolizumab (Keytruda) for hormone receptor-positive, HER2-negative metastatic breast cancer.

West Coast Study Rates Cancer Centers by Cost and Quality

July 17th 2018

In a groundbreaking study of costs and quality of cancer care among cancer clinics in the state of Washington, investigators found wide disparity in end-of-life care, suggesting that improvements in cost and quality could be attained if treatment centers share information on what works and endeavor to improve.

CDK4/6 Inhibitors Continue to Revolutionize ER+ Breast Cancer Care

July 16th 2018

Yelena Novik, MD, discusses the application of CDK4/6 inhibition and methods to overcome resistance in ER-positive breast cancer.

Dr. Ellis on Resistance to Endocrine Therapy in HR+ Metastatic Breast Cancer

July 13th 2018

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses resistance to endocrine therapy in hormone receptor (HR)-positive breast cancer.

Dr. Woodward on Radiotherapy in Breast Cancer

July 13th 2018

Wendy A. Woodward, MD, PhD, professor and chief, Clinical Breast Radiotherapy Service, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses radiotherapy in breast cancer.

Dr. Tripathy on the Management of HR+ Early-Stage Breast Cancer

July 13th 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the management of hormone-receptor (HR)-positive early-stage breast cancer.

Other Novel Targets and Future Outlook in Breast Cancer

July 12th 2018

ADCs & Checkpoint Inhibitor Combinations in TNBC

July 12th 2018

Chemotherapy and PARP Inhibitors in BC

July 12th 2018

Clinical Data on Extended Adjuvant Therapy in HR+ BC

July 12th 2018

Role of Adjuvant Denosumab in Early Breast Cancer

July 12th 2018

Patient Selection for Adjuvant Therapy in EBC

July 12th 2018

Treating gBRCA1/2-Mutated HR+ Breast Cancer

July 12th 2018

Clinical Rationale for PI3K Inhibitors in BC

July 12th 2018

Sequencing and Role of Everolimus in HR-Positive Breast Cancer

July 12th 2018

HR-Positive Breast Cancer: Predictive Biomarkers

July 12th 2018